Gold Prices Rebound as Fed Rate Hike Bets Rise 
India Manufacturing Growth Slows to Five-Year Low in August 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Oil Prices Jump as U.S.-Iran Tensions Threaten Hormuz 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Brazil, US Resume Tariff Talks as Trade Tensions Persist 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Global Markets Brace for Fed Rate Hike as Oil Tops $91 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Bessent Says Yen Moves Contained as BOJ Rate Decision Looms 
Dollar Holds Near Two-Week High as Fed Rate Hike Bets Rise 
Bessent Urges Japan on Fiscal Discipline, BOJ Rate Hikes 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Canada Backs €100B Global Defence Bank as G7 Support Lags 
Add as a preferred source on Google
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
